Functionalist Oncology to Model the Contextuality of Dynamics and Treatment in Acute Myeloid Leukaemia
IET Systems Biology · 2026-01 · 20 (1)
DOI: 10.1049/syb2.70073 ↗Kurz gefasst
Fachartikel in der Zeitschrift IET Systems Biology, online erschienen am 01.06.2026. Verfasst von Alexander Ehmann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Models, Biological. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Radiumhemmets Forskningsfonder, Vetenskapsrådet, Svenska Läkaresällskapet.
Abstract (Originalsprache)
Acute myeloid leukaemia (AML) is a disease with high intra‐ and interpatient heterogeneity. Current treatments are still based on cytarabine combined with an anthracycline, with 5‐year overall survival rates below 30%. Functionalist oncology utilises edge‐weighted digraphs as a representational tool to model the mathematical functional interdependencies of disease factors. This methodology enables a conceptual and mechanistic analysis of key factors influencing therapeutic success, providing a framework that can be parameterised to explore patient‐specific treatment responses. It incorporates the oligoclonal nature of AML to perform, in principle, comprehensive cost‐benefit analyses regarding the addition of individual drugs to existing treatment regimens and the number and type of chemotherapy courses to be given. Extrapolating from experimental data, we investigate the therapeutic potential and risks of SAMHD1 inhibitors in AML treatment as a proof‐of‐concept. We also provide a web‐based interactive application to visualise hypothetical AML treatment scenarios, which can be combined with ex vivo single‐cell phenotypic (gene expression), genotypic (somatic mutations) and functional (drug responses) analyses. Functionalist oncology can thus be used to generate testable hypotheses that might contribute to improving oncological decision‐making, for example, by identifying the optimal number, nature and sequence of chemotherapy courses, including both existing and novel drugs, such as SAMHD1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
- Department of Medicine Huddinge, Center for Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.
- Medical Unit Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
- Quantitative Cell Biology (QCB) Consulting, Manglieu, France.
- Paediatric Oncology, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Nikolas Herold
Förderung
- Radiumhemmets Forskningsfonder
- Vetenskapsrådet
- Svenska Läkaresällskapet
- Barncancerfonden
- Stockholm County Council
- Felix Mindus
- Karolinska Institutet Foundations
- Swedish Society for Medical Research
Zitieren
APA
Ehmann, A., Naboulsi, R., Jädersten, M., Tollis, S., & Herold, N. (2026). Functionalist Oncology to Model the Contextuality of Dynamics and Treatment in Acute Myeloid Leukaemia. IET Systems Biology, 20(1). https://doi.org/10.1049/syb2.70073
Vancouver
Ehmann A, Naboulsi R, Jädersten M, Tollis S, Herold N. Functionalist Oncology to Model the Contextuality of Dynamics and Treatment in Acute Myeloid Leukaemia. IET Systems Biology. 2026;20(1). doi:10.1049/syb2.70073
BibTeX
@article{Ehmann2026,
author = {Ehmann, Alexander and Naboulsi, Rakan and Jädersten, Martin and Tollis, Sylvain and Herold, Nikolas},
title = {Functionalist Oncology to Model the Contextuality of Dynamics and Treatment in Acute Myeloid Leukaemia},
journal = {IET Systems Biology},
year = {2026},
volume = {20},
number = {1},
doi = {10.1049/syb2.70073}
}
EUVIMED